Q-omics provides the consensus-scored OLIG3 profile across patient tissues and cancer cell-line models. OLIG3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, OLIG3 is differentially expressed in 4, with the highest sampling consensus in UCEC. Additionally, OLIG3 RNA expression shows 8,465 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, UCEC, and TGCT as cancer lineages where OLIG3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OLIG3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OLIG3 survival associations across molecular data types. OLIG3 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OLIG3 RNA expression–survival associations across cancer types. High OLIG3 expression shows unfavorable associations in BRCA, STAD, UCEC, KIRC and BLCA, but favorable associations in SCLC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for OLIG3 RNA expression.
This table summarizes OLIG3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for OLIG3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OLIG3 shows higher tumor expression in UCEC, PRAD, KIRP and LUAD. The UCEC box plot shows higher OLIG3 RNA expression in tumor versus normal tissue (log2 FC = +0.386, t-test p = .001).
This table shows molecular features associated with OLIG3 in patient tissues and cancer cell lines. In patient samples, OLIG3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, OLIG3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and STOMACH.
